ClinicalTrials.gg
CompletedNCT07230184Updated Sep 4, 2026

To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR

A Phase 4 interventional study of B55R1 and B55R2 and B55R1 and placebo for B55R2 in Non-Proliferative Diabetic Retinopathy, sponsored by AJU Pharm Co., Ltd.. Completed at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by AJU Pharm Co., Ltd. · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 3 years 4 months after the study started (first participant enrolled Apr 2022, registered Sep 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 14 studies in Diabetic Retinopathy with a site in Korea, Republic of — 2 open to participants now, 4 under way, none of them phase 3. Diabetic Retinopathy · Korea, Republic of.

Enrollment
5th of 11
53 · median 49
Started
2022
with 1 other
Phase 4
4 of 14
none open now
Registered
12th of 14
by date
Lead sponsor
1 of 14
AJU Pharm Co., Ltd.

Among the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, this one is the 5th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 in phase 4, and was the 12th registered.

Diabetic Retinopathy

783 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

2 of the 14 studies in Diabetic Retinopathy with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Diabetic Retinopathy with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is planned to evaluate the efficacy and safety of combination therapy with B55R1 and B55R2 compared to B55R1 monotherapy in patients with non-proliferative diabetic retinopathy (NPDR).

03

Conditions studied

  • Non-Proliferative Diabetic Retinopathy

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged 19 years or older as of the date of written consent.
  2. Patients diagnosed with type 1 or type 2 diabetes.
  3. Subjects with mild to severe nonproliferative diabetic retinopathy (diabetic retinopathy), grade 2-5 hard exudates
  4. Subjects with a best-corrected visual acuity (BCVA) of 0.33 or higher as determined by visual acuity testing.
  5. Subjects with a central retinal thickness of 350 µm or less as determined by optical coherence tomography (OCT).
  6. Subjects who have received an explanation of the purpose and methods of this clinical trial and voluntarily consented to participate.

Exclusion criteria

Exclusion Criteria:

  1. Patients with proliferative diabetic retinopathy (diabetic retinopathy) or other causes of retinopathy.
  2. Patients with uncontrolled diabetes or uncontrolled hypertension.
  3. Patients with the following ocular diseases or surgical procedures:

    - Visual field defects, media opacity and ocular diseases other than diabetic retinopathywhich the investigator determines may affect the evaluation.

  4. Patients who have received intravitreal and periocular injections, intravitreal injection of anti-VEGF antibodies (anti-VEGF treatment), or laser photocoagulation within 12 weeks of the date of administration of the drug
  5. Patients taking Kallidinogenase, Vaccinium myrtillus extract, or Sulodexide
  6. Patients who have experienced a cardiovascular event (unstable angina, myocardial infarction, , stroke, etc.) within 24 weeks prior to Visit 1 (participation is possible if the event occurred 24 weeks prior to Visit 1 and the patient is currently receiving medication in a stable condition)
  7. Patients with severe renal impairment (renal failure requiring dialysis or (e.g., renal transplant)
  8. Patients with a history of within the past 5 years from the time of screening. However, the following are eligible for clinical trial participation:

    • More than 5 years have passed since the cancer was diagnosed as cured from the screening.
    • Basal cell carcinoma, squamous cell carcinoma of the skin, thyroid cancer, or other intraepithelial neoplasms
  9. Pregnant or lactating women, or those who do not agree to use adequate during the clinical trial.
  10. Those who have received another investigational drug within 12 weeks prior to Visit 1
  11. Those who are judged by the investigator to be unsuitable for clinical trial participation due to other medical or psychiatric findings
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Test group(B55R1 and B55R2)

    orally twice daily

    Drug: B55R1 and B55R2

  • Placebo comparator
    Control Group(B55R1 and placebo for B55R2)

    orally twice daily

    Drug: B55R1 and placebo for B55R2

Interventions

  • DrugB55R1 and B55R2

    After Randomization(Week 0), Participants will be administered with the drug, 2 times in a day, until end of trial(Week 24).

  • DrugB55R1 and placebo for B55R2

    After Randomization(Week 0), Participants will be administered with the drug, 2 times in a day, until end of trial(Week 24).

06

What researchers measure

Primary outcomes

  1. The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 24

    The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Changes in CMT as measured by OCT at Week 4, 12 and 24

    Changes in CMT as measured by OCT at Week 4, 12 and 24

    Time frame: Week 4, 12 and 24

  2. The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 4 and 12

    The proportion of subjects achieving a ≥1-step improvement in hard exudate grade at Week 4 and 12

    Time frame: Week 4 and 12

07

Study locations

1 site
  • AJU Pharm Co., Ltd.
    Seoul, South Korea
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Aug 2023, 15 months.

Of 32 phase 4 interventional studies under Diabetic Retinopathy, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2025
First posted
Nov 17, 2025
StartActual
Apr 28, 2022
Primary completionActual
Aug 14, 2023
CompletionActual
Aug 16, 2024
Last update
Sep 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07230184
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Apr 28, 2022
Primary completion
Aug 14, 2023
Completion
Aug 16, 2024
Last update
Sep 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion